✦ LIBER ✦

A caspase-generated epitope of Tau measured in serum predicts progression of disease in early Alzheimer's disease patients

✍ Scribed by Henriksen, Kim; Inekci, Dilek; Duffin, Kevin; Dean, Bob; Karsdal, Morten

Book ID: 123368660
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 51 KB
Volume: 9
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.04.055

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Co-localization of hyperphosphorylated t

Co-localization of hyperphosphorylated tau and caspases in the brainstem of Alzheimer’s disease patients

✍ Maria Sen Mun Wai; Yong Liang; Chun Shi; Eric Y. P. Cho; Hsiang-fu Kung; David T 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 498 KB

Propagation of Tau Pathology in a Model

Propagation of Tau Pathology in a Model of Early Alzheimer’s Disease

✍ de Calignon, Alix; Polydoro, Manuela; Suárez-Calvet, Marc; William, Christopher; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Caspase-9 Activation and Caspase Cleavag

Caspase-9 Activation and Caspase Cleavage of tau in the Alzheimer's Disease Brain

✍ Troy T. Rohn; Robert A. Rissman; Michael C. Davis; Young Eun Kim; Carl W. Cotman 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 390 KB

A novel serum biomarker measuring degrad

A novel serum biomarker measuring degradation of tau allows the detection of Alzheimer's disease in serum samples

✍ Henriksen, Kim; Pedersen, Jan Torleif; Duffin, Kevin; Wang, Yaguo; Christiansen, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 183 KB

Mutation screening of the tau gene in pa

Mutation screening of the tau gene in patients with early-onset Alzheimer's disease

✍ Gerwin Roks; Bart Dermaut; Peter Heutink; Ann Julliams; Hubert Backhovens; Marle 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Measurement of progression in Alzheimer'

Measurement of progression in Alzheimer's disease: a clinician's perspective

✍ Douglas J. Gelb 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

Patients with Alzheimer's disease (AD) and their families must confront two fundamental truths. First, AD is a uniformly progressive disease that ultimately results in debilitating cognitive impairment. Second, although there is now evidence that some medications may produce transient improvement or